Atara Biotherapeutics, which has its research and development headquarters in Westlake Village, filed with the Securities and Exchange Commission on Jan. 2 to hold a $100 million secondary public offering. Atara develops treatments for diseases including cancer, autoimmune disorders and viruses using T-cell immunotherapies. The company said it expects to sell around 5.5 million shares…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
